



## MARCH 2025 QUARTERLY ACTIVITY REPORT

### HIGHLIGHTS

- Preparations underway for two IND-enabling pre-clinical studies for intravitreal administration of EmtinB
- NSB to acquire StemSmart™ patented Stem Cell technology (StemSmart), for the manufacture of life-changing cellular medicine, Mesenchymal Stromal Cells (MSC), from Isopogen WA Ltd (Isopogen WA)<sup>1</sup>
- Early indications from the Phase 2 trial in refractory Crohn's disease suggest StemSmart™ MSC is potent, efficacious and safe<sup>1</sup>
- StemSmart™ MSC is derived from adult human donor bone marrow. The MSCs are isolated and grown in culture, before the patented StemSmart™ manufacturing process is applied to improve the cells' clinical efficacy<sup>1</sup>
- StemSmart™ MSC works by interacting with a patient's immune system to modulate immune responses<sup>1</sup>
- MSCs respond to inflammation by secreting factors that reduce the activation and proliferation of immune cells and down-regulate their production of inflammatory mediators<sup>1</sup>
- Patients both locally and interstate have already received StemSmart™ MSC therapy on compassionate grounds, for a variety of serious and life-threatening clinical conditions, with multiple strong positive clinical responses<sup>1</sup>
- The US FDA recently approved the first mesenchymal stromal cell (MSC) therapy (Mesoblast ASX Announcement 19.12.2024 (ASX: MSB)). This decision paves the way for renewed enthusiasm and global investment in clinical research of MSC therapies<sup>1</sup>
- Cash balance of A\$4.3M at 31 March 2025

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) ("**NeuroScientific**" or "**the Company**") today submitted its Appendix 4C and quarterly activity report for the period ended 31 March 2025.

### IND-enabling studies for EmtinB in advanced glaucoma

During the quarter, NSB continued to prepare two IND-enabling studies of EmtinB to prepare for its first-in-human trials targeting adults with advanced glaucoma. The first study will be a non-GLP pharmacokinetics (PK) study of intravitreally administered EmtinB in rabbits. In parallel, the Company is planning a 13-week evaluation of ocular tolerance, systemic toxicity and pharmacokinetics in vitreous following repeated intravitreal administrations also in rabbits.

<sup>1</sup>ASX Announcement 16 April 2025.

## Acquisition of StemSmart technology from Isopogen (Subsequent to quarter end)

On April 16, NSB announced that it had entered into binding agreements in relation to the Company's proposed acquisition of 100% of the issued shares in the capital of Isopogen WA (**Acquisition**). Isopogen WA holds 100% of the issued shares in Isopogen Pty Ltd (both referred to hereafter as **Isopogen**), which holds or has the rights to exploit the StemSmart™ patented technology. Isopogen WA is a public unlisted biotech company advancing innovative cell therapies using its proprietary platform technology StemSmart™ through its wholly owned subsidiary Isopogen Pty Ltd.

The Acquisition is subject to a number of conditions precedent, including each of the shareholders of Isopogen WA signing a separate share sale agreement with the Company. The Company has received signed share sale agreements from each of the Key Sellers, which collectively hold 51.4% of the issued share capital of Isopogen WA.

Contemporaneous with the Acquisition, the Company has received firm commitments to raise up to \$3.5 million (before costs) under a Placement (defined below) and intends to appoint current Isopogen WA directors Robert McKenzie and Paul Fry to the Company's board of directors to progress the development of StemSmart. Importantly, Dr Marian Sturm will be appointed as Chief Scientific Adviser at Completion.

### PLACEMENT

Firm commitments have been received from the Company's Lead Manager, Westar Capital, to raise \$3.5 million (before costs) at a share price of \$0.035 each via a placement to professional, sophisticated and qualifying investors<sup>1</sup>.

### STEMSMART KEY ADRESSABLE MARKETS

- **Crohn's Disease:** Global market US\$13.8 billion by 2026<sup>1</sup>;
- **Kidney Transplant:** Global market for organ transplant immuno-suppressants, increasing to US\$7.2 billion by 2030<sup>1</sup> (majority for renal);
- **Lung Disorders:** Global market US\$33 billion by 2034<sup>1</sup>; and
- **GvHD:** Global market increasing to US\$0.640 billion in 2026<sup>1</sup>.

### CONDITIONS PRECEDENT TO THE ACQUISITION

Completion is subject to the satisfaction or waiver of various conditions precedent, including (but not limited to) the following:

- each Isopogen WA shareholder executing a share sale agreement (**SSA**) in respect of their Isopogen WA shares and the Company be entitled to complete under each SSA;
- the Company obtaining shareholder approval pursuant to ASX Listing Rules 7.1 and 10.11 (to the extent required) for the issue of the Consideration Shares, Performance Shares, Placement Shares and Debt Conversion Shares at the General Meeting<sup>1</sup>;
- the parties obtaining any required third party approvals, consents and waivers and regulatory approvals to give effect to the Acquisition; and
- no material adverse change having occurred with respect to Isopogen.

For personal use only

Each SSA may be terminated in certain circumstances including (but not limited to) by either the Company or the Isopogen WA shareholder if the conditions precedent are not satisfied (or waived, as permitted) within 120 days of the signing of the relevant SSA.

#### **CORPORATE**

The Company lodged its half year report and accounts on 26 February 2025.

#### **QUARTERLY CASH FLOW SUMMARY**

NeuroScientific's cash position was \$4.3 million as at 31 March 2025. The Company has maintained a strong cash position with expenses continuing to be carefully managed.

Research and development activity payments during the current quarter were \$39k (\$21k for the prior quarter ("PQ")). Staff costs for the quarter were \$62k (PQ - \$83k). Administration and corporate costs were \$61k (PQ -\$192k).

Payments to related parties during the March 2025 quarter totalled \$62k and relate to Director fees, salaries and superannuation.

The level of net cash burn for the June 2025 quarter is expected to moderately increase, in line with the proposed acquisition of Isopogen and the corresponding work required to progress this acquisition towards completion. The Company continues to actively advance its IND-enabling studies for EmtinB in glaucoma.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Tony Keating  
Executive Director  
[tony@neuroscientific.com](mailto:tony@neuroscientific.com)  
+61 8 6382 1805

Chris Achurch  
Company Secretary  
[ir@neuroscientific.com](mailto:ir@neuroscientific.com)  
+61 8 6382 1805

### **About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

### **About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

NeuroScientific Biopharmaceuticals Limited

**ABN**

13 102 832 995

**Quarter ended ("current quarter")**

31 March 2025

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(39)	(97)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(62)	(212)
(f) administration and corporate costs	(61)	(396)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	55	137
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (exclusivity fee)	(75)	(75)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(182)</b>	<b>(643)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of period	4,493	4,954
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(182)	(643)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-

For personal use only

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>4,311</b>	<b>4,311</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	862	1,267
5.2	Call deposits	3,449	3,226
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>4,311</b>	<b>4,493</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(62)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>Item 6.1 above includes Director salaries, fees &amp; superannuation.</p>		

7. <b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-
7.5 <b>Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(182)
8.2 Cash and cash equivalents at quarter end (item 4.6)	4,311
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	4,311
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	23.69
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: n/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: n/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: n/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

For personal use only

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 24 April 2025

Authorised by: The Board of Directors

For personal use only